Background and Purpose-Atrial fibrillation has been considered a risk factor for poor outcome from acute stroke and may influence response to thrombolysis, although supporting data are limited due to potential confounding with age and stroke severity. Method-We assessed the association of atrial fibrillation and thrombolysis exposure with the modified Rankin Scale score distribution at 90 days among patients registered in a trials archive. We used an age and baseline National Institutes of Health Stroke Scale-adjusted Cochran-Mantel-Haenszel test to test significance (P) followed by proportional odds logistic regression analysis to estimate the ORs for improved modified Rankin Scale score. Results-Data were available for 7091 patients, of whom 3027 were thrombolyzed. A total of 1631 patients had a history of atrial fibrillation, of whom 639 were thrombolyzed. Among patients with atrial fibrillation, baseline severity was greater (median baseline National 
O ne in 3 patients treated by thrombolysis within 3 hours of ischemic stroke onset achieves significant benefit, 1 raising the question whether a factor such as comorbidity would identify patients in whom treatment would confer no measurable advantage. Age, diabetes, and prior stroke appear unlikely to influence treatment response, but another comorbidity such as atrial fibrillation may be a candidate. 2, 3 Atrial fibrillation (AF) is an independent risk factor for stroke and increases its incidence nearly 5-fold. 4 The attributable risk of stroke for AF rises with age, from 1.5% for those aged 50 to 59 years to 23.5% for those aged 80 to 89 years. 4 There are theoretical reasons for questioning whether thrombolysis will have a different effect among patients with AF versus sinus rhythm. On the one hand, patients with AF may have old emboli which after reaching intracranial vessels are unlikely to dissolve with alteplase 5 ; on the other hand, they might have soft emboli formed at ruptured sites of membranous thrombi and that are at least in theory amenable to thrombolysis, whereas cholesterol emboli from carotid lesions, small-vessel occlusion, and other nonembolic causes of stroke should be less responsive to treatment. In association with the factors that may influence clot dissolution, the timing of restoration of blood flow and the abruptness could also have an influence on the risk of hemorrhagic transformation with or without thrombolysis.
Thus, the question arises whether patients with stroke with AF gain significant benefit from thrombolysis.
The few studies that have been conducted on this subject showed that patients with stroke with AF more frequently had a poor outcome after treatment with alteplase when compared with those without AF. [5] [6] [7] [8] However, they did not compare with a control group, which has not been given alteplase. Among the randomized controlled trials examining efficacy of alteplase in patients with stroke, results for the AF subgroup are described only for the European Cooperative Acute Stroke Study (ECASS) III and National Institute of Neurological Disorders and Stroke (NINDS) trials. In the NINDS trial, disregarding treatment groups, AF was significantly associated with worse global outcome (OR for more favorable outcome, 0.57; 95% CI, 0.38 -0.86) but there was no significant interaction with treatment and further data were not reported. 9 In the ECASS III trial, there was a nonsignificant trend among the subgroup of patients with AF (alteplase nϭ53, control nϭ55) that favored placebo over alteplase treatment (OR, 0.68; 95% CI, 0.30 -1.55). 10 A small retrospective study compared patients with stroke with AF who were (nϭ22) or were not (nϭ44) treated with alteplase. Here, by contrast, there were significantly improved odds of favorable outcome for patients with AF when treated with alteplase (OR, 2.67; 95% CI, 1.06 -6.74). 11 In our present analysis, we sought to further investigate influence of AF on outcome in thrombolyzed patients with stroke. Thereby we aimed at providing answers to the question, if these patients should be treated differently.
Methods

Data Source and Patients
We gathered demographics, clinical data, and functional outcome measures from neuroprotection trials in ischemic stroke conducted in the period from 1998 to 2008. We obtained our data, anonymized in relation to patients and trials, from the Virtual International Stroke Trials Archive (VISTA). 12 We excluded trials that had tested effects of thrombolysis or of any drug now known to influence outcome after stroke. We excluded patients who lacked relevant baseline and outcome information: baseline National Institutes of Health Stroke Score (NIHSS), age, history of AF, alteplase administration as standard of care, occurrence of adverse events as well as serious adverse events, and modified Rankin Scale (mRS) at Day 90. Death was recorded as mRS grade 6. Symptomatic recurrent strokes and symptomatic intracerebral hemorrhages (ICHs) were defined as any stroke/ICH with neurological deterioration, as indicated by an NIHSS at 24 hours that was higher by Ն4 points than the value at baseline or any stroke/ICH leading to death. Patients receiving oral anticoagulation at stroke onset or up to 3 days poststroke were excluded.
Statistical Analysis
A nonrandomized adjusted comparison of outcomes was conducted, differentiating between patients with and without a history of AF and between patients who received alteplase versus patients who did not. Analysis was adjusted for age and baseline NIHSS, which has previously been justified in detail. 13, 14 Because VISTA is anonymized for trial source, the precise definition of AF could not be established, although few acute trials define this in any case. Therefore, it is possible that a few patients with AF were misclassified as non-AF.
Our primary outcome measure was the distribution of mRS at 90 days using the full scale. 13 For comparison with prior trials and reports, dichotomized outcomes at 90 days (mRS 0 -1, mRS 0 -2, NIHSS 0 -1, and mortality) were reported. Additionally, information of occurrence of recurrent strokes and ICHs in the first 3 days after stroke onset were retrieved from adverse event and serious adverse event data and reported.
Unadjusted baseline comparisons were conducted using the 2-sample t test, the Mann-Whitney U test, the 2 proportions test, or the 2 test depending on the distribution and nature of the data. Correlations (r) were calculated using the Spearman rank correlation coefficient, which takes into account the ordinal nature of the mRS. The coefficient of variation (r 2 ) was calculated from these correlations.
Reported ORs express the odds of improved outcome in association with alteplase treatment or presence of AF, respectively, adjusted for specified covariates. ORs and 95% CIs of ordinal outcome measures were computed using ordinal logistic regression and probability values computed using the Cochran-MantelHaenszel test. Dichotomized outcome measures were assessed using binary logistic regression.
The significance of the interaction between AF and thrombolysis; AF, age, and thrombolysis; and age on mRS at Day 90 were investigated. Plots of the effect of AF and effect of thrombolysis (patients with AF only) on full-scale mRS at Day 90 against age were constructed to investigate the effect over age.
Analyses were undertaken using SAS 9.2, PASW Statistics 18, StatsDirect 2.7.8, and R Version 2.10.0.
Results
Baseline Characteristics
We collected data from 7091 patients with ischemic stroke of whom 3027 (42.7%) were thrombolyzed within 3 hours of stroke onset. A total of 1631 (23.0%) patients had a known history of AF at the time of hospital admission of whom 639 (39.2%) were thrombolyzed. Patients with AF were much older (mean 7.5-year difference) and had a higher baseline NIHSS (median 2-point difference). Age accounted for 8% (rϭ0.28) and baseline NIHSS for 24% (rϭ0.49) of the variation in mRS at Day 90 (both PϽ0.001) and these variables were included in all models (together r 2 approximately 29%). History of diabetes, previous myocardial infarction, and systolic blood pressure were not different between groups (online-only Data Supplement Table I ). Detailed information of significantly different baseline characteristics is given in Table 1 .
Outcome
Irrespective of AF status, the mRS scores at Day 90 had a more favorable distribution among thrombolyzed patients than comparators ( Figure 1 ). Adjusted for baseline NIHSS and age, the OR for improved outcome with thrombolysis was 1.44 in patients with AF (95% CI, 1.12-1.73; PϽ0.001) and 1.53 in non-AF patients (95% CI, 1.39 -1.69; PϽ0.001). Adjustment for all variables that differed at baseline gave broadly unchanged results (online-only Data Supplement).
AF had no influence on mRS at Day 90 after adjusting for baseline NIHSS and age (OR, 0.93; 95% CI, 0.84 -1.03; Pϭ0.409). Again, adjustment for all variables that differed at baseline gave broadly unchanged results. Likewise, this held true also within treatment groups (online-only Data Supplement).
Neither the rates of mortality nor the rates of recurrent strokes differed between patients with stroke with versus without AF nor was there any difference within the AF patient group according to treatment with alteplase versus untreated (online-only Data Supplement Table II) .
Analyses with dichotomized outcomes measured by mRS, NIHSS, and ICH rates are presented in Table 2 .
Interaction of AF and Age
There was no interaction between alteplase treatment and age on outcome among patients with AF (Pϭ0.671; Figure 2A ).
The presence of AF was possibly associated with more favorable outcome among younger patients and less favorable at approximately Ͼ75 years after adjustment for baseline NIHSS and treatment with alteplase ( Figure 2B ). The interaction between AF and age had borderline significance (Pϭ0.010).
Discussion
Despite being older and more severely affected, and thus at risk of poorer outcome than non-AF patients, patients with stroke with AF had a better outcome at 90 days when treated with alteplase than their untreated peers. No interaction between AF and alteplase treatment on outcome was found. Our results were supported by a range of secondary dichotomized measures that we examined.
The hypothesis exists that AF would influence stroke outcome in thrombolyzed patients mainly due to different recanalization rates when compared with patients without AF. 5 However, we conducted a meta-analysis of the limited number of studies on this subject, which showed no overall difference in recanalization rates (Figure 3) . In support of this finding, an analysis of thrombemboli retrieved by endovascular mechanical extraction showed no overall histological difference between clots from cardiac or arterial sources. 18, 19 Besides, one has to keep in mind that a relevant proportion of strokes in patients with AF is of nonembolic origin. 20, 21 The proportion of embolic strokes among patients with AF may be overestimated because most studies use the Trial of ORG 10172 in Acute Stroke Treatment criteria to define stroke etiology. In these, history of AF is sufficient to define a cardioembolic etiology. 22 We confirmed that history of AF had a negative effect on 90-day outcome with lower percentages of favorable clinical outcome when compared with non-AF patients (Figure 1) . Because age and baseline NIHSS together explained 29% of the variability in unadjusted 90-day mRS, it was not surprising that adjusted ORs indicated that AF is not an independent predictor of poor outcome. The observed difference in baseline characteristics is common when investigating AF-related stroke outcome. 7, 11, 23, 24 The group analysis presented here underlines the importance of adjusting for important confounders, which the previous studies have neglected.
When looking at the interaction of age and AF on stroke outcome, our data indicate that AF seems to have an increasingly deleterious effect in elderly patients. This is in line with prior studies showing that age has an independent and additive effect on the hypercoagulable or prothrombotic state in AF. 25, 26 
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We found that the rates of ICH and symptomatic SICH were similar in AF and non-AF patients. Additionally, the ORs for treatment with thrombolysis within patients with AF were comparable with those reported in thrombolysis trials. 27 We found no increase in rates of recurrent stroke in patients with AF. In this study, data for recurrent stroke and ICH have to be interpreted with caution, because patients who are not treated with thrombolysis generally did not undergo follow-up routine cerebral imaging for detection of hemorrhagic transformation or minor recurrent strokes unless there was a symptomatic deterioration. These rates may have been underestimated in the nonthrombolyzed group, leading to potential overestimation of any negative effect of alteplase treatment. Our primary analysis approach overcomes this limitation: dichotomization of mRS outcomes using a cutoff of 1 (favorable outcome) or 2 (good outcome) carries the risk of concealing higher proportions of severely disabled patients within the unfavorable outcome group (eg, more mRS 5 among patients with mRS Ͼ1 or 2). Comparing the full range of mRS limits the risk of missing effects of relevant ICH or recurrent strokes on functional outcome.
An analysis of nonrandomized registry data, whether or not derived from trials, inevitably incorporates selection bias for thrombolytic treatment and other confounders. These have been previously discussed. 13 In summary, these data lend support to the use of alteplase across all age groups of patients with stroke with a history of AF. AF appears to be a marker of high age and baseline NIHSS rather than an independent risk factor for poor stroke outcome and has no discernible impact on the effect of thrombolysis. Odds of more favorable outcome across the full range of 90-day mRS for each year of age. This is presented (A) in patients with AF, contrasting outcomes in patients treated with alteplase versus not treated (ie, interaction of treatment with alteplase and age among patients with AF) after adjustment for baseline NIHSS; and (B) in all patients, contrasting outcomes for patients having AF versus normal rhythm (ie, interaction of AF with age) after adjustment for baseline NIHSS and for treatment with alteplase. mRS indicates modified Rankin Scale; AF, atrial fibrillation; NIHSS, National Institutes of Health Stroke Scale. Odds of recanalization for patients with AF compared with sinus rhythm. Pooled OR for the studies using computed tomography/magnetic resonance angiography (CTA/MRA) 7, 11, 15 and transcranial Doppler (TCD) 16, 17 as well as combined for all studies were estimated using both fixed and random effects models. The pooled estimates from random effects models were used because tests for heterogeneity were significant in all analyses (Cochran Q Pϭ0.0013, I 2 ϭ77.6%). In the study of Kimura et al, 15 patients were treated with 0.6 mg/kg instead of the usual 0.9 mg/kg alteplase; recanalization included complete or partial recanalization. In the studies of Zhang et al 11 and Sanak et al, 7 no exact definition of recanalization was provided. The study of Baizabal et al 16 defined recanalization as having TIBI 5 and the study of Tsivgoulis et al 17 as having TIBI 4 to 5 in TCD. To be included in the meta-analysis, a published study had to meet the following criteria: (1) original article in English; (2) treatment with alteplase in all patients; and (3) recording of recanalization rates in patients with and without AF. A PubMed search was performed using the key words "(atrial fibrillation OR thrombolysis) AND stroke AND recanalization." There were no date limitations and the last search was done in November 2011. AF indicates atrial fibrillation; TIBI, Thrombolysis in Brain Ischemia. 
SUPPLEMENTAL MATERIAL
Outcome analyses adjusted for all significantly different baseline variables
The following results were adjusted for all significantly different baseline variables (sex, age, baseline NIHSS, baseline glucose, hypertension, and diastolic blood pressure at baseline):
The OR for thrombolysis was 1.43 in AF patients (95% CI 1. 
